Introduction
============

Rectal cancer is an increasing, and important disease worldwide ([@b1-ol-0-0-9756]). For patients with American Joint Committee on Cancer (AJCC) stage II or III disease, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy remains the preferred therapy as it has been shown to provide better local control, greater anal preservation, and lesser toxicity ([@b2-ol-0-0-9756]). However, up to 10--20% of these patients will eventually develop local or distal disease recurrence ([@b3-ol-0-0-9756]).

Rectal cancer post neoadjuvant CCRT or not are all staged by using the AJCC tumor-node-metastasis (TNM) staging system, and further adjuvant treatment is recommended. There is no modification of staging for patients who receive neoadjuvant CCRT. Prediction of prognosis using TNM staging is suboptimal, and survival of patients with the same stage disease can vary markedly. Therefore, additional prognostic biomarkers to aid in risk stratification and identify patients who may benefit from more intensive treatment may help to improve outcomes.

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that belongs to the HER family of receptor tyrosine kinases, and promotes multiple signaling cascades for cellular survival, such as RAS/MAPK, PI3K/Akt, Stat, and Src ([@b4-ol-0-0-9756]). Overexpression of cytoplasmic EGFR (EGFR-C) is associated with tumor differentiation, proliferation, and migration, and has been extensively studied as the most important cancer molecular target in recent decades ([@b5-ol-0-0-9756],[@b6-ol-0-0-9756]). Recently, studies have reported that EGFR family members can be transported from the plasma membrane to the nucleus, and regulate target genes involved in cell proliferation and angiogenesis ([@b7-ol-0-0-9756],[@b8-ol-0-0-9756]). The prognostic significance of nuclear EGFR (EGFR-N) has been demonstrated, and is highly associated with tumor progression and worse overall survival (OS) ([@b9-ol-0-0-9756],[@b10-ol-0-0-9756]). It has also been shown to be associated with enhanced resistance to systemic and radiation therapy ([@b7-ol-0-0-9756]). Therefore, overexpression of EGFR-N is frequently a poor prognostic factor. However, little is known about the relevance of EGFR-N in rectal cancer patients treated with neoadjuvant CCRT.

The aim of this study was to evaluate the clinical correlates of EGFR-C and EGFR-N expression in rectal cancer patients after neoadjuvant CCRT, and also to compare the impact of EGFR-N and EGFR-C expression on prognosis.

Materials and methods
=====================

### Ethics statement

The present study was reviewed and approved by the Institutional Review Board of Chi-Mei Medical Center in Taiwan (Tainan, Taiwan; IRB, CMFHR10501-008). The requirement for informed consent was waived as all identifying information was removed from the dataset prior to analysis.

### Patient demographic characteristics and tumor specimens

This retrospective study was performed on formalin-fixed paraffin-embedded (FFPE) tissue specimens from 172 newly diagnosed rectal adenocarcinoma patients treated at Chi-Mei Medical Center between 1998 and 2004. The data was collected and analyzed in February 2014. All patients received preoperative 5-fluorouracil-based chemotherapy concomitant with radiotherapy (45--50 Gy), followed by radical proctectomy with total mesorectal excision. The clinical stage was determined by endoscopic ultrasound (EUS), abdominal computed tomography (CT), or magnetic resonance imaging (MRI) findings. Adjuvant systemic chemotherapy was given if the post-treatment (Post-Tx) tumor or nodal status was beyond T3 or N1. All patients were regularly monitored after diagnosis until death or last follow-up. Patients who had a previous cancer history, distal metastasis at diagnosis, or were unable to complete a full course of CCRT were excluded. The histopathological parameters were reviewed by our pathologist (Dr. Li) who was blind to the patients\' clinical data.

The data extracted from the medical records included the date of diagnosis, age, sex, clinical TNM stage, pathological characteristics such as lymphovascular and perineural invasion, chemotherapy regimen and timing, and cause of death. All patients were re-staged and re-graded according to the 7th edition of the AJCC staging system, and World Health Organization (WHO) classification of Tumors of the Colon and Rectum. The primary endpoints were 5-year disease-specific survival (DSS), local recurrent-free survival (LRFS), and metastases-free survival (MeFS) rates. Deaths due to cancer were defined as valid events, and deaths secondary to other causes were censored.

### Immunohistochemistry analysis

Immunohistochemistry of tissue microarray (TMA) slides and whole sections were prepared as previously described ([@b11-ol-0-0-9756]). Briefly, tissue sections from Pre-Tx rectal tumor biopsies were deparaffinized and rehydrated for EGFR immunostaining. Overexpression of EGFR-C was defined as an intensity of 3+ EGFR reactivity seen in the cytoplasm (and/or membrane) of tumor cells ([@b12-ol-0-0-9756]). To define overexpression, the cutoff percentage of immunoreactive tumor cells was 50% for EGFR-N in this analysis ([@b13-ol-0-0-9756]).

### Statistical analysis

The results are presented as the mean ± standard deviation. All statistical analyses and graphics were performed using IBM SPSS statistical software for Windows, v14.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference. Examination of the associations of EGFR expression with clinicopathological features was conducted using the chi-square test. The Kaplan-Meier method was used to analyze the cumulative 5-year DSS, LRFS, and MeFS rates, and rates were compared using the log-rank test to evaluate prognostic differences between subgroups. The primary event was defined as disease-specific mortality, and survival curves were calculated from the date of diagnosis. Those parameters that demonstrated prognostic significance in the univariate analysis were input into the Cox multivariate regression analysis.

Results
=======

Patient demographic and clinical characteristics are summarized in [Table I](#tI-ol-0-0-9756){ref-type="table"}. A total of 172 rectal cancer patients who underwent neoadjuvant CCRT and radical proctectomy with total mesorectal excision from January 1998 to December 2008 were included. The median age was 63 years (range: 22--88 years). The percentages of patients with initial stage I, II, and III disease were 41.9, 29.9, and 28.1% and all stage II, III patients received adjuvant chemotherapy Fifteen (8.7%) patients presented with lymphovascular invasion, and 5 (2.9%) with perineural invasion.

The results of EGFR immunostaining to investigate EGFR expression in the cytoplasm and the nucleus of rectal tumor tissues are shown in [Fig. 1](#f1-ol-0-0-9756){ref-type="fig"}. Of the patients, 20.9% had EGFR-N overexpression, 23.3% EGFR-C overexpression and 5.2% have both high EGFR-N and high EGFR-C expression. EGFR-N overexpression was significantly related to advanced pre-Tx tumor T-stage (T3, 4; P=0.017) and post-Tx tumor T-stage (T3, 4; P\<0.001). EGFR-C overexpression was significantly related to pre-Tx tumor T-stage (T3, 4; P=0.013), post-Tx tumor T-stage (T3, 4; P=0.004), lymphovascular invasion (P=0.025), and perineural invasion (P=0.048).

### Univariate and multivariate survival analyses for factors predicting survival

In univariate analyses ([Table II](#tII-ol-0-0-9756){ref-type="table"}), post-Tx tumor status and nuclear EGFR expression were significantly correlated with poorer 5-year DSS, LRFS, and MeFS rate (all, P\<0.05).

Pre-Tx nodal status, lymphovascular invasion, and perineural invasion were negatively associated with 5-year DSS and LRFS (all, P\<0.05). Pre-Tx tumor status was significantly associated with poorer 5-year DSS only (P=0.0484). Multivariate analyses results are shown in [Table III](#tIII-ol-0-0-9756){ref-type="table"}. EGFR-N, but not EGFR-C, was an independent prognostic factor for 5-year DSS (hazard ratio \[HR\]=2.755, 95% confidence interval \[CI\]: 1.313--5.783) and LRFS (HR=3.026, 95% CI: 1.224--7.281), but not for MeFS (HR=1.853, 95% CI: 0.852--4.032). Pre-Tx nodal status and post-Tx tumor status were independent prognostic factors for 5-year DSS only (HR=2.640, 95% CI: 1.317--5.290; HR=2.210, 95% CI: 1.084--4.503, respectively).

### EGFR-N overexpression as an independent prognostic factor

Overexpression of EGFR-N, but not EGFR-C, was significantly correlated with poor DSS, LRFS, and MeFS in univariate analyses (all, P\<0.05) ([Table II](#tII-ol-0-0-9756){ref-type="table"}; [Fig. 2](#f2-ol-0-0-9756){ref-type="fig"}). Higher expression of EGFR-N remained an independent predictor of worse DSS and LRFS in multivariate analyses, as shown in [Table III](#tIII-ol-0-0-9756){ref-type="table"} (HR=2.755, 95% CI: 1.3137--5.783; HR=3.026, 95% CI: 1.224--7.281, respectively).

Discussion
==========

There have been great advances in the treatment of rectal cancer in recent decades, and neoadjuvant CCRT followed by radical proctectomy has become primary treatment. However, the long-term survival of rectal cancer patients has remained stagnant. Therefore, it is necessary to find effective predictive biomarkers to stratify high-risk patients for more intensive therapy. In this study, we demonstrated that high expression of EGFR-N, but not EGFR-C, was correlated with aggressive tumor behavior and poor outcome. These results suggest that EGFR-N may be useful for outcome prediction in rectal cancer patients after CCRT, and may possibly be a potential therapeutic target.

Molecular methods usually provide reliable information for cancer patients. However, studies that have evaluated prognostic biological markers for rectal cancer have yielded inconclusive results ([@b14-ol-0-0-9756],[@b15-ol-0-0-9756]). A variety of studies have suggested that overexpression of EGFR was positively correlated with aggressive tumor behavior and poor prognosis in colorectal cancer ([@b12-ol-0-0-9756],[@b16-ol-0-0-9756],[@b17-ol-0-0-9756]). But, there was considerable discrepancy in the frequency and distribution of EGFR expression in previous immunohistochemical studies ([@b18-ol-0-0-9756],[@b19-ol-0-0-9756]). Many of these studies provided speculative information on the association of protein expression and clinicopathological features. Furthermore, in clinical trials evaluating the efficacy of cetuximab, treatment response was not related to the level of EGFR expression; many patients with colorectal cancer expressing EGFR failed to respond to treatment, and those with EGFR negative tumors responded to therapy. A possible reason that EGFR levels are a poor predictor of response to anti-EGFR therapies is disparity between the form or epitope of EGFR detected by immunohistochemistry and the one targeted by anti-EGFR monoclonal antibodies ([@b7-ol-0-0-9756]).

Recent evidence has suggested that EGFR can translocate to the nucleus ([@b7-ol-0-0-9756]). After activation, the nuclear translocation of EGFR has been shown to be dependent on phosphorylation events by many intracellular kinases such as SRC family and AKT ([@b9-ol-0-0-9756]). The nuclear transport of EGFR is guided by COPI-mediated vesicular trafficking from the Golgi to the endoplasmic reticulum (ER) ([@b20-ol-0-0-9756]). After being shuttled into the ER membrane, EGFR and importin β1 interface in the nuclear pore complex, and shuttle EGFR from the outer to the inner nuclear membrane. Once in the nucleus, the function of EGFR is widely different from its plasma membrane bound counterpart. EGFR-N is involved in many cellular signaling pathways such as cell proliferation, tumor behavior, DNA synthesis, and DNA repair ([@b21-ol-0-0-9756]--[@b24-ol-0-0-9756]). EGFR-N also plays a functional role in the response to molecular therapeutic agents, and has been linked to poor prognosis in a variety of malignancies ([@b9-ol-0-0-9756],[@b10-ol-0-0-9756],[@b25-ol-0-0-9756]). Hadzisejdic *et al* ([@b10-ol-0-0-9756]), reported that higher EGFR-N staining was associated with shorter OS in breast cancer patients. Overexpression of EGFR-N carried a 3.4-times greater mortality risk as compared to EGFR-N negative patients (HR=3.402; P=0.0026). Hoshino *et al* ([@b25-ol-0-0-9756]), also demonstrated that EGFR-N was associated with an increase in the malignant potential of esophageal squamous cell carcinoma that may affect the prognosis these patients. These intriguing findings emphasize the relevance of evaluating both EGFR-C and EGFR-N expression in colorectal cancer in order to provide additional independent prognostic information.

Our results showed that EGFR-N overexpression was significantly related to advanced pre-Tx tumor T-stage (T3, 4; P=0.017) and post-Tx tumor T-stage (T3, 4; P\<0.001). In multivariate survival analysis, EGFR-N expression was also correlated with worse 5-year DSS and LRFS. These findings are different than those of prior studies where EGFR-C was associated with aggressive tumor behavior and poor outcomes ([@b17-ol-0-0-9756],[@b19-ol-0-0-9756]). Similar to our study, Doger *et al* ([@b16-ol-0-0-9756]) evaluated 60 colon tumor specimens and reported that EGFR-C expression did not predict lymph nodes metastasis or survival. Moreover, EGFR-N overexpression was significantly associated with worse 5-year DSS (HR=2.755, P=0.007) and LRFS (HR=3.026, P=0.0164), but not MeFS (HR=1.85, P=0.12). The possible reasons for these findings may be that nuclear translocation of EGFR decreases cell survival, and is associated with enhanced resistance to radiation and chemotherapy ([@b7-ol-0-0-9756]). EGFR-N is correlated with increased DNA-dependent protein kinase (DNA-PK) activity, which plays an essential role in DNA damage repair and radioresistance ([@b26-ol-0-0-9756]). Thus, the overexpression of EGFR-N in rectal cancers could contribute to the identification of patients who have an increased risk of local recurrences and poor outcomes after neoadjuvant CCRT.

The present study has some limitations. First, the number of patients was relatively small, and the findings should be verified by larger-scale studies. Second, our study cohort included some early-stage rectal cancer patients because of the intention of organ preservation via neoadjuvant CCRT. Further studies focused on locally advanced rectal cancer should be performed. Finally, our results are applicable to only patients with non-metastatic rectal cancer who undergo CCRT.

In summary, the present study revealed that overexpression of EGFR-N, but not EGFR-C, may help identify and stratify high-risk patients after neoadjuvant CCRT. The strong inverse correlation with DFS and LFRS suggested that EGFR-N may be a potential prognostic biomarker and promising therapeutic target.
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![EGFR-C and EGFR-N expression by staining intensity using immunohistochemistry in rectal cancer tissue microarray. (A) EGFR low expression (magnification, ×400); (B) EGFR-C high expression; (magnification: Main, ×400; insert, ×600) and (C) EGFR-N high expression (magnification: Main, ×400; insert, ×600). EGFR-C, cytoplasmic epidermal growth factor receptor; EGFR-N, nuclear epidermal growth factor receptor.](ol-17-02-1551-g00){#f1-ol-0-0-9756}

![Kaplan-Meier analysis of the 5-year disease-specific survival, local recurrence-free survival and metastasis-free survival for rectal cancer patients with (A-C) EGFR-C and (D-F) EGFR-N expression. EGFR-C, cytoplasmic epidermal growth factor receptor; EGFR-N, nuclear epidermal growth factor receptor.](ol-17-02-1551-g01){#f2-ol-0-0-9756}

###### 

Associations and comparisons between Nuclear/Cytoplasmic epidermal growth factor receptor expression and clinicopathological factors in 172 rectal cancer patients.

                                                    EGFR-N (n)        EGFR-C (n)                                                         
  ------------------------------- ----------- ----- ------------ ---- ------------------------------------------------------ ----- ----- ----------------------------------------------------
  Gender                          Male        108   84           24   0.0768                                                 82    26    0.741
                                  Female      64    51           13                                                          50    14    
  Age                             \<60        65    51           14   0.995                                                  49    16    0.742
                                  ≥60         107   84           23                                                          83    24    
  Pre-Tx tumor status (Pre-T)     T1-T2       81    70           11   0.017^[a](#tfn1-ol-0-0-9756){ref-type="table-fn"}^     69    12    0.013^[a](#tfn1-ol-0-0-9756){ref-type="table-fn"}^
                                  T3-T4       91    65           26                                                          63    28    
  Pre-Tx nodal status (Pre-N)     N0          125   101          24   0.229                                                  103   22    0.004^[b](#tfn2-ol-0-0-9756){ref-type="table-fn"}^
                                  N1-N2       47    34           13                                                          29    18    
  Post-Tx tumor status (Post-T)   T1-T2       86    77           9    \<0.001^[c](#tfn3-ol-0-0-9756){ref-type="table-fn"}^   71    15    0.071
                                  T3-T4       86    58           28                                                          65    25    
  Post-Tx nodal status (Post-N)   N0          123   99           24   0.312                                                  99    24    0.066
                                  N1-N2       49    36           13                                                          33    16    
  Lymphovascular invasion         Absent      157   123          34   0.881                                                  124   33    0.025^[a](#tfn1-ol-0-0-9756){ref-type="table-fn"}^
                                  Present     15    12           3                                                           8     7     
  Perineural invasion             Absent      167   131          36   0.933                                                  130   37    0.048^[a](#tfn1-ol-0-0-9756){ref-type="table-fn"}^
                                  Present     5     4            1                                                           2     3     
  Cytoplasmic EGFR expression     Low Exp.    132   105          27   0.540                                                  n/a   n/a   n/a
                                  High Exp.   40    30           10                                                          n/a   n/a   

P\<0.05

P\<0.01

P\<0.001. EGFR-C, cytoplasmic epidermal growth factor receptor; EGFR-N, nuclear epidermal growth factor receptor; Pre-Tx, pre-treatment; Post-Tx, post-treatment; Exp., expression; n/a, not applicable.

###### 

Univariate log-rank analysis for important clinicopathological variables and epidermal growth factor receptor expression.

                                                             DSS             LRFS                                                  MeFS                                                                                  
  ------------------------------- ----------- -------------- --------------- ----------------------------------------------------- --------------- ----------------------------------------------------- --------------- -----------------------------------------------------
  Parameter                       Variable    No. of cases   No. of events   P-value                                               No. of events   P-value                                               No. of events   P-value
  Gender                          Male        108            20              0.6027                                                5               0.3096                                                14              0.1047
                                  Female      64             11                                                                    17                                                                    15              
  Age                             \<60        65             13              0.3259                                                7               0.7575                                                17              0.0052^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^
                                  ≥60         107            18                                                                    15                                                                    12              
  Pre-Tx tumor status (Pre-T)     T1-T2       81             10              0.0484^[a](#tfn4-ol-0-0-9756){ref-type="table-fn"}^   7               0.0836                                                10              0.1288
                                  T3-T4       91             21                                                                    15                                                                    19              
  Pre-Tx nodal status (Pre-N)     N0          125            19              0.0059^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^   12              0.0025^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^   18              0.0866
                                  N1-N2       47             21                                                                    10                                                                    11              
  Post-Tx tumor status (Post-T)   T1-T2       86             12              0.0006^[c](#tfn6-ol-0-0-9756){ref-type="table-fn"}^   5               0.0056^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^   8               0.0123^[a](#tfn4-ol-0-0-9756){ref-type="table-fn"}^
                                  T3-T4       86             34                                                                    17                                                                    21              
  Post-Tx nodal status (Post-N)   N0          123            31              0.3442                                                15              0.6267                                                20              0.8403
                                  N1-N2       49             15                                                                    7                                                                     9               
  Lymphovascular invasion         Absent      157            38              0.0107^[a](#tfn4-ol-0-0-9756){ref-type="table-fn"}^   17              0.0023^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^   26              0.7236
                                  Present     15             8                                                                     5                                                                     3               
  Perineural invasion             Absent      167            43              0.0297^[a](#tfn4-ol-0-0-9756){ref-type="table-fn"}^   20              0.0083^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^   28              0.8157
                                  Present     5              3                                                                     2                                                                     1               
  Cytoplasmic EGFR expression     Low Exp.    132            33              0.6480                                                16              0.6884                                                20              0.3363
                                  High Exp.   40             13                                                                    6                                                                     9               
  Nuclear EGFR expression         Low Exp.    135            28              0.0005^[c](#tfn6-ol-0-0-9756){ref-type="table-fn"}^   12              0.0014^[b](#tfn5-ol-0-0-9756){ref-type="table-fn"}^   18              0.0182^[a](#tfn4-ol-0-0-9756){ref-type="table-fn"}^
                                  High Exp.   37             18                                                                    10                                                                    11              

P\<0.05

P\<0.01

P\<0.001. EGFR-C, cytoplasmic epidermal growth factor receptor; EGFR-N, nuclear epidermal growth factor receptor; Pre-Tx, pre-treatment; Post-Tx, post-treatment; DSS, disease-specific survival; LRFS, local-recurrence-free survival; MeFS, metastases-free survival; Exp., expression.

###### 

Multivariate analysis.

                                              DSS     LRFS           MeFS                                                                                                                                                       
  ------------------------------- ----------- ------- -------------- ----------------------------------------------------- ------- --------------- ----------------------------------------------------- ------- -------------- -----------------------------------------------------
  EGFR-N                          Low Exp.    1       --             0.0061^[b](#tfn8-ol-0-0-9756){ref-type="table-fn"}^   1       --              0.0164^[a](#tfn7-ol-0-0-9756){ref-type="table-fn"}^   1       --             0.1200
                                  High Exp.   2.418   1.287--4.543                                                         3.026   1.224--7.281                                                          1.853   0.852--4.032   
  Pre-Tx nodal status (Pre-N)     N0          1       --             0.0062^[b](#tfn8-ol-0-0-9756){ref-type="table-fn"}^   1       --              0.0948                                                --      --             --
                                  N1-N2       2.640   1.317--5.290                                                         2.308   0.865--6.157                                                          --      --             --
  Post-Tx tumor status (Post-T)   T1-T2       1       --             0.0291^[a](#tfn7-ol-0-0-9756){ref-type="table-fn"}^   1       --              0.1217                                                1       --             0.0587
                                  T3-T4       2.210   1.084--4.503                                                         2.305   0.800--6.637                                                          2.257   0.971--5.247   
  Age, years                      ≥60         1       --             0.0203^[a](#tfn7-ol-0-0-9756){ref-type="table-fn"}^   --      --              --                                                    1       --             0.0112^[a](#tfn7-ol-0-0-9756){ref-type="table-fn"}^
                                  \<60        0.205   1.183--3.765                                                         --      --                                                                    2.608   1.243--5.469   
  Lymphovascular invasion         Absent      1       --             0.0651                                                1       --              0.0683                                                --      --             --
                                  Present     2.213   0.951--5.149                                                         2.780   0.926--8.345                                                          --      --             
  Pre-Tx tumor status (Pre-T)     T1-T2       1                      0.8048                                                --      --              --                                                    --      --             --
                                  T3-T4       1.091   0.460--1.824                                                         --      --                                                                    --      --             
  Perineural invasion             Absent      1                      0.8397                                                1       --              0.4012                                                --      --             --
                                  Present     1.145   0.236--3.249                                                         1.999   0.397--10.075                                                         --      --             

P\<0.05

P\<0.01. EGFR-C, cytoplasmic epidermal growth factor receptor; EGFR-N, nuclear epidermal growth factor receptor; Pre-Tx, pre-treatment; Post-Tx, post-treatment; DSS, disease-specific survival; LRFS, local-recurrence-free survival; MeFS, metastases-free survival; HR, hazard ratio; CI, confidence interval.
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